Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Merck & Company, Inc.
MRK
$120.63
Name : Merck & Company, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $298,232,283,136.00
EPSttm : 7.28
finviz dynamic chart for MRK
Merck & Company, Inc.
$120.63
0.28%
$0.335
MRK — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

1.18

Margin Of Safety %

-17

Put/Call OI Ratio

0.7

EPS Next Q Diff

0.75

EPS Last/This Y

-2.17

EPS This/Next Y

4.64

Price

120.31

Target Price

129.5

Analyst Recom

1.83

Performance Q

12.82

Upside

111.8%

Beta

0.29

Ticker: MRK




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-02MRK121.230.661.17566185
2026-03-04MRK120.260.671.59578366
2026-03-05MRK116.030.670.73592601
2026-03-09MRK116.930.680.76591199
2026-03-10MRK117.090.690.38591840
2026-03-11MRK116.40.690.21594710
2026-03-12MRK115.910.690.28598931
2026-03-17MRK115.850.820.87536310
2026-03-18MRK114.50.811.65539652
2026-03-19MRK114.20.820.67544691
2026-03-20MRK114.180.800.85555582
2026-03-23MRK115.670.740.88469664
2026-03-24MRK116.380.730.34483251
2026-03-25MRK119.380.690.30499175
2026-03-26MRK118.930.670.82514201
2026-03-27MRK1200.680.36518577
2026-03-30MRK118.150.700.54505647
2026-03-31MRK120.310.701.35511447
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-02MRK121.35-158.7-4641.45.13
2026-03-03MRK119.82-159.1-4530.25.11
2026-03-04MRK120.29-159.1-4254.95.11
2026-03-05MRK116.04-159.0-4888.55.12
2026-03-06MRK115.78-159.0-4353.35.12
2026-03-09MRK117.12-159.0-3926.55.12
2026-03-10MRK117.09-159.0-4116.85.12
2026-03-11MRK116.21-159.0-4449.15.12
2026-03-12MRK115.93-159.0-4365.25.12
2026-03-13MRK115.61-159.0-4368.85.12
2026-03-17MRK115.88-159.0-4144.95.12
2026-03-18MRK114.46-159.0-4405.45.12
2026-03-19MRK114.22-159.0-5436.65.12
2026-03-20MRK114.18-159.0-5402.15.12
2026-03-23MRK115.75-159.0-5190.95.12
2026-03-24MRK116.37-159.5-5308.75.13
2026-03-25MRK119.38-159.0-5006.15.13
2026-03-26MRK118.96-159.0-5445.65.13
2026-03-27MRK119.62-159.0-5418.25.13
2026-03-30MRK118.11-159.0-5697.75.13
2026-03-31MRK120.31-159.0-5223.15.13
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-02MRK-13.800.761.14
2026-03-03MRK-13.800.761.14
2026-03-04MRK-13.800.761.14
2026-03-05MRK-13.800.761.14
2026-03-06MRK-13.800.761.14
2026-03-09MRK-13.800.521.14
2026-03-10MRK-13.800.521.14
2026-03-11MRK-13.800.521.26
2026-03-12MRK-13.800.521.26
2026-03-13MRK-13.800.521.26
2026-03-17MRK-13.800.611.26
2026-03-18MRK-13.790.611.26
2026-03-19MRK-13.800.611.26
2026-03-20MRK-13.800.611.26
2026-03-23MRK-13.790.531.26
2026-03-24MRK-13.790.531.26
2026-03-25MRK-13.800.531.18
2026-03-26MRK-13.800.531.18
2026-03-27MRK-13.800.531.18
2026-03-30MRK-13.800.531.18
2026-03-31MRK-13.800.531.18
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

1.19

Avg. EPS Est. Current Quarter

-1.31

Avg. EPS Est. Next Quarter

1.94

Insider Transactions

-13.8

Institutional Transactions

0.53

Beta

0.29

Average Sales Estimate Current Quarter

15877

Average Sales Estimate Next Quarter

16390

Fair Value

100.15

Quality Score

96

Growth Score

77

Sentiment Score

98

Actual DrawDown %

10.6

Max Drawdown 5-Year %

-43.4

Target Price

129.5

P/E

16.53

Forward P/E

12.42

PEG

2

P/S

4.58

P/B

5.66

P/Free Cash Flow

24.06

EPS

7.28

Average EPS Est. Cur. Y​

5.13

EPS Next Y. (Est.)

9.76

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

28.12

Relative Volume

0.88

Return on Equity vs Sector %

7.3

Return on Equity vs Industry %

-1.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-5223.1
MRK Healthcare
$120.29
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
12/20
Pullback
12/25
Volume
7/15
Valuation
5/20
TP/AR
3/10
Options
3/10
RSI
59.3
Range 1M
65.5%
Sup Dist
3.3%
🚀
Momentum Growth
Ride accelerating trends
N/A
37 /100
WEAK
Momentum
8/25
Growth
11/30
Estimates
7/20
Inst/Vol
6/15
Options
5/10
EPS Yr
-43%
EPS NY
89.3%
52W%
89.9%
💎
Long-Term Value
Quality companies, undervalued
63 /100
WATCH
🟢 BUY +88.5% upside
Quality
29/30
Valuation
17/30
Growth
9/25
Stability
6/10
LT Trend
2/5
Upside
+88.5%
Quality
96
MoS
-17%
Merck & Company, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
MRK

Latest News

Caricamento notizie per MRK
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading